Cellular Biomedicine Group, Inc. Form 5 February 13, 2015

rebluary 15, 2015									
FORM 5			OMB AF	PROVAL					
UNITED ST. Check this box if	ATES SECURITIES AND EXCHANGE Washington, D.C. 20549	S SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							
5 obligations may continue.									
1(b). Filed pursua	See Instruction 1(b).Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,Form 3 Holdings Reported Form 4Section 17(a) of the Public Utility Holding Company Act of 1935 or SectionSouth Act of 1935 or Section30(h) of the Investment Company Act of 1940TransactionsTransactions								
1. Name and Address of Reporting Pers Liu Tony	son <u>*</u> 2. Issuer Name <b>and</b> Ticker or Trading Symbol Cellular Biomedicine Group, Inc. [CBMG]	5. Relationship of Issuer (Check	Reporting Pers						
(Last) (First) (Mide	(Month/Day/Year) 01/03/2014	X Director X Officer (give below) Chief F		Owner er (specify er					
530 UNIVERSITY AVENUE, # (Street)	4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joi (check	int/Group Repo	U					
PALO ALTO, CA 94301		_X_ Form Filed by C Form Filed by M Person							

(City)	(State)	(Zip) Tal	ble I - Non-De	rivative Securities Ac	quired, Disposed	of, or Beneficia	lly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or Amount (D) Price	5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information SEC 2270 contained in this form are not required to respond unless (9-02) the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and A
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction	Derivative	Expiration Date	Underlying Se
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired (A) or		

## Edgar Filing: Cellular Biomedicine Group, Inc. - Form 5

	Derivative Security			Disposed of (D) (Instr. 3, 4, and 5)					
					(A)	(D)	Date Exercisable	Expiration Date	Title
Non-Qualified Stock Option	\$ 5	01/03/2014	Â	A4	255,000	Â	(1)	01/03/2024	Common Stock

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Liu Tony 530 UNIVERSITY AVENUE, #17 PALO ALTO, CA 94301	X	Â	Chief Financial Officer	Â			
Signatures							
/s/Bizuo (Tony)							

/s/B1zuo (1 ony) Liu <u>\*\*</u>Signature of Reporting Person 02/13/2015

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This option vests according to the following schedule: 1/36th per month following the vesting commencement date of January 3, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.